CHEMOTHERAPY-INDUCED HYPOCALCEMIA

被引:3
作者
Ajero, Pia Marie E. [1 ]
Belsky, Joseph L. [1 ]
Prawius, Herbert D. [1 ]
Rella, Vincent [1 ]
机构
[1] Danbury Hosp, Dept Med Endocrinol & Oncol, Danbury, CT 06810 USA
关键词
BONE METASTASES; CALCIUM; HYPOPARATHYROIDISM; CYCLOPHOSPHAMIDE; TRANSPLANTATION; DACARBAZINE; CISPLATIN; VITAMIN; PATIENT;
D O I
10.4158/EP09137.RA
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To present a unique case of transient, asymptomatic chemotherapy-induced hypocalcemia not attributable to hypomagnesemia or tumor lysis syndrome and review causes of hypocalcemia related to cancer with and without use of chemotherapy. Methods: We present a case detailing the clinical and laboratory findings of a patient who had severe hypocalcemia during chemotherapy and discuss causes of hypocalcemia with an extensive literature review of chemotherapeutic agents associated with this biochemical abnormality. Results: In a 90-year-old man, hypocalcemia developed during 2 courses of chemotherapy for Hodgkin lymphoma, with partial recovery between courses and normal serum calcium 10 months after completion of treatment. Magnesium, vitamin D. and parathyroid hormone levels were low normal. There was no evidence of tumor lysis syndrome. Of the various agents administered, vinca alkaloids seemed the most likely cause. Serial testing suggested that the underlying mechanism may have been acquired, reversible hypoparathyroidism. No other similar case was found in the published literature. Conclusion: The severe hypocalcemia in our patient could not be attributed to hypomagnesemia or tumor lysis syndrome, and it was clearly associated with the timing of his chemotherapeutic regimen. Possibilities include direct parathyroid hormone suppression or alteration of calcium sensing by the chemotherapeutic drugs. Serum calcium surveillance before and during chemotherapeutic management of cancer patients may reveal more instances and provide insight into the exact mechanism of this lesser known yet striking complication. (Endocr Pract. 2010;16:284-290)
引用
收藏
页码:284 / 290
页数:7
相关论文
共 24 条
[1]   A PHASE-I CLINICAL AND PHARMACOLOGICAL PROFILE OF DACARBAZINE WITH AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN PATIENTS WITH SOLID TUMORS [J].
ADKINS, DR ;
IRVIN, R ;
KUHN, J ;
BOLDT, DH ;
ROODMAN, GD ;
SALZMAN, D ;
FREYTES, C ;
VONHOFF, DD ;
LEMAISTRE, CF .
INVESTIGATIONAL NEW DRUGS, 1993, 11 (2-3) :169-179
[2]   PHASE-I TRIAL OF DACARBAZINE WITH CYCLOPHOSPHAMIDE, CARMUSTINE, ETOPOSIDE, AND AUTOLOGOUS STEM-CELL TRANSPLANTATION IN PATIENTS WITH LYMPHOMA AND MULTIPLE-MYELOMA [J].
ADKINS, DR ;
SALZMAN, D ;
BOLDT, D ;
KUHN, J ;
IRVIN, R ;
ROODMAN, GD ;
LYONS, R ;
SMITH, L ;
FREYTES, CO ;
LEMAISTRE, CF .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (09) :1890-1901
[3]  
Bergkamp FJM, 2003, NETH J MED, V61, P371
[4]  
CALANDRA DB, 1984, SURGERY, V96, P1132
[5]   Hypocalcemia following pamidronate administration for bone metastases of solid tumor: Three clinical case reports [J].
Champallou, C ;
Basuyau, JP ;
Veyret, C ;
Chinet, P ;
Debled, M ;
Chevrier, A ;
Grongnet, MH ;
Brunelle, P .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2003, 25 (02) :185-190
[6]   ACTION OF VINCA ALKALOIDES ON CALCIUM MOVEMENTS THROUGH MITOCHONDRIAL-MEMBRANE [J].
CHANTAL, T ;
NANCY, F ;
CLAUDETTE, B ;
GASTON, D ;
AIME, C .
PHARMACOLOGICAL RESEARCH COMMUNICATIONS, 1986, 18 (06) :519-528
[7]  
CHERTOW BS, 1975, LAB INVEST, V32, P190
[8]   Hypocalcemia associated with bone metastases in a patient with salivary-gland carcinoma [J].
Dawson, SJ ;
Murray, RML ;
Rischin, D .
NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (02) :104-107
[9]  
FITZGERALD PA, 2007, 2008 CURRENT MED DIA, P988
[10]   HYPOPARATHYROIDISM AND HYPOCALCEMIA DURING TREATMENT FOR ACUTE-LEUKEMIA [J].
FREEDMAN, DB ;
SHANNON, M ;
DANDONA, P ;
PRENTICE, HG ;
HOFFBRAND, AV .
BRITISH MEDICAL JOURNAL, 1982, 284 (6317) :700-702